Andrew Dudum Sells 36,460 Shares of Hims & Hers Health, Inc. (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 36,460 shares of Hims & Hers Health stock in a transaction on Thursday, January 16th. The stock was sold at an average price of $27.09, for a total transaction of $987,701.40. Following the completion of the sale, the chief executive officer now owns 27,918 shares of the company’s stock, valued at approximately $756,298.62. This trade represents a 56.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Andrew Dudum also recently made the following trade(s):

• On Tuesday, January 21st, Andrew Dudum sold 300 shares of Hims & Hers Health stock. The stock was sold at an average price of $30.00, for a total transaction of $9,000.00.
• On Monday, December 16th, Andrew Dudum sold 78,127 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.62, for a total transaction of $2,314,121.74.
• On Monday, December 2nd, Andrew Dudum sold 33,513 shares of Hims & Hers Health stock. The stock was sold at an average price of $33.38, for a total value of $1,118,663.94.
• On Tuesday, November 5th, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.88, for a total value of $3,943,981.44.

Hims & Hers Health Stock Performance

NYSE:HIMS opened at $30.90 on Friday. The stock has a market cap of $6.75 billion, a price-to-earnings ratio of 70.22 and a beta of 1.31. Hims & Hers Health, Inc. has a 1 year low of $8.51 and a 1 year high of $35.02. The business has a fifty day moving average of $27.98 and a 200-day moving average of $22.09.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million during the quarter, compared to analyst estimates of $382.20 million. During the same quarter in the prior year, the firm posted ($0.04) EPS. Hims & Hers Health’s revenue was up 77.1% compared to the same quarter last year. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Quest Partners LLC boosted its stake in Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after purchasing an additional 807 shares in the last quarter. Stonekeep Investments LLC lifted its holdings in shares of Hims & Hers Health by 5.5% in the fourth quarter. Stonekeep Investments LLC now owns 16,952 shares of the company’s stock valued at $410,000 after buying an additional 882 shares during the period. CWM LLC boosted its stake in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock valued at $110,000 after buying an additional 1,054 shares in the last quarter. Cadent Capital Advisors LLC grew its holdings in Hims & Hers Health by 1.5% during the fourth quarter. Cadent Capital Advisors LLC now owns 72,160 shares of the company’s stock worth $1,745,000 after acquiring an additional 1,060 shares during the period. Finally, Raleigh Capital Management Inc. raised its position in Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the company. Citigroup downgraded Hims & Hers Health from a “neutral” rating to a “sell” rating and boosted their price target for the company from $24.00 to $25.00 in a report on Friday, January 10th. Needham & Company LLC lifted their price objective on shares of Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, January 6th. Morgan Stanley initiated coverage on shares of Hims & Hers Health in a report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price on the stock. BTIG Research started coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 price target for the company. Finally, Deutsche Bank Aktiengesellschaft increased their price objective on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a research note on Wednesday, November 6th. Two investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company. Based on data from MarketBeat.com, Hims & Hers Health has a consensus rating of “Hold” and a consensus target price of $25.13.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.